Gyre Therapeutics, Inc. (NASDAQ:GYRE) President Songjiang Ma Sells 2,000 Shares

Gyre Therapeutics, Inc. (NASDAQ:GYRE) President Songjiang Ma sold 2,000 shares of the company’s stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $11.90, for a total value of $23,800.00. Following the completion of the transaction, the president now directly owns 2,877,138 shares of the company’s stock, valued at $34,237,942.20. This represents a 0.07 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Songjiang Ma also recently made the following trade(s):

• On Tuesday, February 4th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $11.62, for a total transaction of $23,240.00.
• On Wednesday, January 29th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $11.43, for a total value of $22,860.00.
• On Monday, January 27th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $11.18, for a total transaction of $22,360.00.
• On Thursday, January 23rd, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $10.49, for a total value of $20,980.00.
• On Tuesday, January 21st, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $10.85, for a total transaction of $21,700.00.
• On Friday, January 17th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $10.72, for a total value of $21,440.00.
• On Wednesday, January 15th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.85, for a total value of $21,700.00.
• On Monday, January 13th, Songjiang Ma sold 56 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.10, for a total transaction of $565.60.
• On Friday, January 10th, Songjiang Ma sold 1,057 shares of Gyre Therapeutics stock. The stock was sold at an average price of $10.02, for a total transaction of $10,591.14.
• On Monday, January 6th, Songjiang Ma sold 941 shares of Gyre Therapeutics stock. The stock was sold at an average price of $10.16, for a total transaction of $9,560.56.

Gyre Therapeutics Trading Up 0.4 %

GYRE stock traded up $0.05 during trading on Wednesday, reaching $11.62. The stock had a trading volume of 30,824 shares, compared to its average volume of 87,447. Gyre Therapeutics, Inc. has a one year low of $8.26 and a one year high of $26.37. The company’s 50 day moving average is $11.13 and its two-hundred day moving average is $12.35.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. FMR LLC bought a new position in Gyre Therapeutics during the third quarter valued at about $47,000. Barclays PLC grew its position in shares of Gyre Therapeutics by 281.8% during the 3rd quarter. Barclays PLC now owns 9,288 shares of the company’s stock valued at $116,000 after acquiring an additional 6,855 shares during the period. Bank of New York Mellon Corp raised its holdings in shares of Gyre Therapeutics by 11.1% in the 4th quarter. Bank of New York Mellon Corp now owns 13,896 shares of the company’s stock worth $168,000 after purchasing an additional 1,389 shares during the period. Advantage Alpha Capital Partners LP purchased a new position in Gyre Therapeutics in the third quarter valued at approximately $334,000. Finally, SBI Securities Co. Ltd. bought a new position in Gyre Therapeutics during the fourth quarter valued at $1,225,000. Institutional investors own 23.99% of the company’s stock.

About Gyre Therapeutics

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.